Puma Biotechnology Q1 revenue falls on weaker NERLYNX sales; raises 2026 outlook

Puma Biotechnology

07/05/2026 22:03

Overview

US cancer drugmaker's Q1 revenue fell yr/yr as NERLYNX sales declined

Adjusted EPS and net income improved vs prior yr but remained negative

Company raised 2026 revenue and net income guidance on higher NERLYNX demand

Outlook

Puma raises 2026 full-year net product revenue guidance to $202–206 mln from $194–198 mln

Company lifts 2026 full-year net income forecast to $16–19 mln from $10–13 mln

Puma expects expansion of ALISCA-Breast1 and ALISCA-Lung1 trials in H2 2026

Result Drivers

R&D SPENDING - Higher research and development expenses driven by increased alisertib clinical trial activity

OPERATING COSTS - Increased selling, general and administrative expenses mainly due to higher employee compensation and marketing costs

DEBT REDUCTION - Lower interest expense and improved other income due to continued debt repayments

Company press release: ID:nBwbbxjfSa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
$42 mln
Q1 Adjusted EPS
Beat
-$0.04
-$0.13 (1 Analyst)
Q1 EPS
-$0.07
Q1 Adjusted Net Income
Beat
-$1.90 mln
-$6.80 mln (1 Analyst)
Q1 Net Income
-$3.80 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.00, about 32.9% below its May 6 closing price of $7.45

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)